InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
dcaf7 Free
03/11/24 6:42 PM
profile icon
Awl416 Free
03/11/24 7:13 AM
profile icon
BooDog Free
03/01/24 4:01 PM
profile icon
jdheart101 Free
02/13/24 11:47 PM
profile icon
TIMGZ Free
02/09/24 12:59 PM
profile icon
BooDog Free
02/09/24 11:43 AM
Bullish
Bullish
profile icon
glenn1919 PremiumMember
02/04/24 1:56 PM
profile icon
jdheart101 Free
01/25/24 4:27 PM
profile icon
jdheart101 Free
01/23/24 9:55 PM
profile icon
BooDog Free
12/06/23 10:35 AM
Bullish
Bullish
profile icon
BooDog Free
10/31/23 4:18 PM
Bullish
Bullish
profile icon
glenn1919 PremiumMember
10/14/23 9:06 AM
profile icon
TRADER99 Free
10/10/23 5:11 PM
profile icon
Monksdream PremiumMember
10/02/23 4:17 PM
profile icon
BooDog Free
09/26/23 6:33 PM
profile icon
Monksdream PremiumMember
09/24/23 1:25 PM
profile icon
Monksdream PremiumMember
09/21/23 3:11 PM
profile icon
Monksdream PremiumMember
09/20/23 1:31 PM
profile icon
Monksdream PremiumMember
09/18/23 1:15 PM
profile icon
BooDog Free
08/07/23 2:04 PM
profile icon
BooDog Free
06/26/23 7:12 AM
profile icon
BooDog Free
06/07/23 12:30 PM
profile icon
BooDog Free
06/06/23 7:16 AM
profile icon
BooDog Free
06/01/23 8:45 AM
profile icon
TIMGZ Free
05/31/23 12:49 PM
profile icon
BooDog Free
05/30/23 1:50 PM
profile icon
BooDog Free
05/23/23 7:35 AM
Bullish
Bullish
profile icon
BooDog Free
05/11/23 10:07 AM
Bullish
Bullish
profile icon
glenn1919 PremiumMember
05/06/23 7:42 AM
profile icon
BooDog Free
05/04/23 10:26 AM
Bullish
Bullish
profile icon
BooDog Free
04/17/23 9:50 AM
Bullish
Bullish
profile icon
BooDog Free
04/14/23 10:51 AM
Bullish
Bullish
profile icon
BooDog Free
03/06/23 9:36 AM
Bullish
Bullish
profile icon
makinezmoney Free
03/03/23 10:38 AM
profile icon
BooDog Free
11/10/22 10:44 AM
profile icon
BooDog Free
10/26/22 10:48 AM
profile icon
BooDog Free
09/16/22 3:47 PM
profile icon
BooDog Free
09/01/22 9:41 AM
profile icon
BooDog Free
08/12/22 11:44 AM
profile icon
BooDog Free
08/10/22 3:51 PM
profile icon
BooDog Free
07/18/22 3:15 PM
profile icon
BooDog Free
07/15/22 9:45 AM
profile icon
BooDog Free
07/12/22 6:29 AM
profile icon
BooDog Free
06/29/22 5:08 PM
profile icon
BooDog Free
04/19/22 6:24 AM

Lexicon Pharmaceuticals Inc (LXRX) RSS Feed

Followers
55
Posters
168
Posts (Today)
0
Posts (Total)
763
Created
02/27/05
Type
Free
Moderators

Results From SOLOIST and SCORED Outcomes Studies Presented at Late-Breaking Science Session of American Heart Association Scientific Sessions and Published in The New England Journal of Medicine

 
 
Lexicon Pharmaceuticals, Inc.
Mon, November 16, 2020, 10:02 PM EST
 
 

Sotagliflozin Significantly Reduced Total Cardiovascular Deaths, Heart Failure Hospitalization and Urgent Visits, Achieving Primary Endpoint in Both Studies

THE WOODLANDS, Texas, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced that both the SOLOIST and SCORED Phase 3 studies achieved their primary endpoints by demonstrating statistically significant reductions in total cardiovascular deaths, hospitalizations for heart failure and urgent heart failure visits in patients treated with sotagliflozin as compared with placebo.

In the SOLOIST study, the primary endpoint was achieved with a hazard ratio (HR) of 0.67 (p<0.001) in people with type 2 diabetes and a recent hospitalization for worsening heart failure. In the SCORED study, the primary endpoint was achieved with a hazard ratio of 0.74 (p<0.001) in people with type 2 diabetes and chronic kidney disease with an estimated glomerular filtration rate (eGFR) of 25 to 60 ml/minute per 1.73 m² of body-surface area.

 

The key results from SOLOIST and SCORED were presented today at the Late-Breaking Science Session of the American Heart Association (AHA) Scientific Sessions 2020 and simultaneously published in The New England Journal of Medicine (NEJM) in two separate articles titled: “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure” and “Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.” The articles may be accessed at www.nejm.org.

“Cardiovascular disease continues to be a leading cause of death in people with type 2 diabetes,” said Deepak L. Bhatt, M.D., M.P.H., executive director of Interventional Cardiovascular Programs at Brigham and Women's Hospital and a professor of medicine at Harvard Medical School and study chair and lead author for the NEJM publications of the SOLOIST and SCORED results. “SOLOIST demonstrates that early, in-hospital initiation of sotagliflozin in patients with worsening heart failure significantly reduces subsequent cardiovascular events, an effect that was consistent across groups with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). SCORED demonstrates that sotagliflozin significantly reduces heart failure events in a patient population with stage 3 and 4 chronic kidney disease and cardiovascular risk. Both studies add to the evidence that SGLT2 inhibition should be standard of care in heart failure, and the SCORED data reflecting a reduction in myocardial infarction and stroke and better glucose control in CKD patients suggest potential benefits from the dual SGLT1 and SGLT2 mechanism of this particular agent.”

 
 
New Post